LSMW to engineer new facility for Ferring Pharmaceuticals

Published: 13-Oct-2003


Ferring Pharmaceuticals, of Kiel, Germany, a subsidiary of Ferring BV, has placed an order with M+W Zander's subsidiary LSMW to engineer and construct a new turnkey production facility. The NFF facility (new freeze-drying facility) will fill and freeze-dry pharmaceutical products in accordance with the latest European Good Manufacturing Practices (GMP) and the US FDA requirements. Freeze-drying plays an increasingly important role in the pharmaceutical/biotech industry, especially for biotechnologically produced products. The process to be employed, known as lyophilisation, is an optimal drying method, which extends the lifetime of temperature-sensitive medicines. In addition to the construction and technical infrastructure, LSMW´s order includes the delivery and assembly of the cleanroom technology and production equipment for the 4,600m2, four-storey site, including its qualification and validation. Production at the site is scheduled to begin in the second half of 2005. Ferring is a pharmaceutical group that identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology.

T: +49 711 88040 info@mw-zander.com

You may also like